Association between attention-deficit hyperactivity disorder in childhood and schizophrenia later in adulthood

European Psychiatry

Volumn 29, Issue 4, 2014, Pages 259-263

  Dalsgaard, S ^a,b,c,d   Mortensen, P B ^a,d   Frydenberg, M ^a   Maibing, C M ^e   Nordentoft, M ^d,e   Thomsen, P H ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Hospital of Telemark   (Norway)

^d H LUNDBECK A S   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Attention deficit hyperactivity disorder (ADHD); Methylphenidate; Pharmacoepidemiology; Prevalence; Psychotic disorders; Schizophrenia

Indexed keywords

DEXAMPHETAMINE; METHYLPHENIDATE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; ICD-10; ICD-8; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA; TREATMENT DURATION; COMPLICATION; PRESCHOOL CHILD; RISK;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SCHIZOPHRENIA;

EID: 84899915443     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2013.06.004     Document Type: Article

References (70)

1. Abel K.M., Wicks S., Susser E.S., Dalman C., Pedersen M.G., Mortensen P.B., et al. Birth weight, schizophrenia, and adult mental disorder: is risk confined to the smallest babies?. Arch Gen Psychiatry 2010, 67:923-930.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders, Fourth Edition, Text Revision (DSM-IV-TR) 2000, American Psychiatric Association, Washington, DC.
3. Biederman J., Faraone S., Milberger S., Curtis S., Chen L., Marrs A., et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1996, 35:343-351.
4. Biederman J., Faraone S., Milberger S., Guite J., Mick E., Chen L., et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 1996, 53:437-446.
5. Biederman J., Monuteaux M.C., Mick E., Spencer T., Wilens T.E., Silva J.M., et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006, 36:167-179.
6. BootsMiller B.J., Ribisl K.M., Mowbray C.T., Davidson W.S., Walton M.A., Herman S.E. Methods of ensuring high follow-up rates: lessons from a longitudinal study of dual diagnosed participants. Subst Use Misuse 1998, 33:2665-2685.
7. Carpenter M.D., Winsberg B.G., Camus L.A. Methylphenidate augmentation therapy in schizophrenia. J Clin Psychopharmacol 1992, 12:273-275.
8. Cherland E., Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year review. Can J Psychiatry 1999, 44:811-813.
9. Crow T.J., Done D.J., Sacker A. Childhood precursors of psychosis as clues to its evolutionary origins. Eur Arch Psychiatry Clin Neurosci 1995, 245:61-69.
10. Dalsgaard S., Hansen N., Mortensen P.B., Damm D., Thomsen P.H. Reassessment of ADHD in a historical cohort of children treated with stimulants in the period 1969-1989. Eur Child Adolesc Psychiatry 2001, 10:230-239.
11. Dalsgaard S., Mortensen P.B., Frydenberg M., Thomsen P.H. Conduct problems, gender and adult psychiatric outcome of children with attention-deficit hyperactivity disorder. Br J Psychiatry 2002, 181:416-421.
12. Dalsgaard S., Mortensen P.B., Frydenberg M., Thomsen P.H. Long-term criminal outcome of children with attention deficit hyperactivity disorder. Crim Behav Ment Health 2013, 23:86-98.
13. Dalsgaard S., Nielsen H.S., Simonsen M. Five-fold increase in national prevalence rates of ADHD medications for children and adolescents with Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disorder and other psychiatric disorders-A Danish register-based study. J Child Adolesc Psychopharmacol 2013, 23:432-438.
14. Davidson M., Reichenberg A., Rabinowitz J., Weiser M., Kaplan Z., Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 1999, 156:1328-1335.
15. de la Serna E., Baeza I., Toro J., Andres S., Puig O., Sanchez-Guistau V., et al. Relationship between clinical and neuropsychological characteristics in child and adolescent first degree relatives of subjects with schizophrenia. Schizophr Res 2010, 116:159-167.
16. Dichter G.S., Damiano C.A., Allen J.A. Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. J Neurodev Dis 2012, 4:19.
17. Ekinci O., Sabuncuoglu O. Psychosis associated with switching from risperidone to aripiprazole in an adolescent on methylphenidate treatment. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:648-649.
18. Faraone S.V., Biederman J., Mennin D., Gershon J., Tsuang M.T. A prospective four-year follow-up study of children at risk for ADHD: psychiatric, neuropsychological, and psychosocial outcome. J Am Acad Child Adolesc Psychiatry 1996, 35:1449-1459.
19. Fischer M., Barkley R.A., Fletcher K.E., Smallish L. The adolescent outcome of hyperactive children: predictors of psychiatric, academic, social, and emotional adjustment. J Am Acad Child Adolesc Psychiatry 1993, 32:324-332.
20. Galynker I., Ieronimo C., Miner C., Rosenblum J., Vilkas N., Rosenthal R. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci 1997, 9:231-239.
21. Gelperin K., Phelan K. Psychiatric adverse events associated with drug treatment of ADHD: review of postmarketing safety data. FDA Report PID D050243 2006, US Food and Drug Administration, [Last accessed March 26th 2013]. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_11_01_AdverseEvents.pdf.
22. Gerlach J., Bjorndal N., Christensson E. Methylphenidate, apomorphine, THIP, and diazepam in monkeys: dopamine-GABA behavior related to psychoses and tardive dyskinesia. Psychopharmacology (Berl) 1984, 82:131-134.
23. Gershon J. A meta-analytic review of gender differences in ADHD. J Atten Disord 2002, 5:143-154.
24. Greiner C., Enss E., Haen E. [Drug-induced psychosis after intake of a modified-release formulation of methylphenidate]. Psychiatr Prax 2009, 36:89-91.
25. Hasson R., Fine J.G. Gender differences among children with ADHD on continuous performance tests: a meta-analytic review. J Atten Disord 2012, 16:190-198.
26. Hechtman L. Predictors of long-term outcome in children with attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999, 46:1039-1052.
27. Hellgren L., Gillberg I.C., Bagenholm A., Gillberg C. Children with deficits in attention, motor control and perception (DAMP) almost grown up: psychiatric and personality disorders at age 16years. J Child Psychol Psychiatry 1994, 35:1255-1271.
28. Helzer J.E. Standardized interviews in psychiatry. Psychiatr Dev 1983, 1:161-178.
29. Hurtig T.M., Taanila A., Veijola J., Ebeling H., Maki P., Miettunen J., et al. Associations between psychotic-like symptoms and inattention/hyperactivity symptoms. Soc Psychiatry Psychiatr Epidemiol 2011, 46:17-27.
30. IBM Corp. IBM SPSS Statistics version 19.0.0 2010, IBM Corp., Armonk, NY.
31. Janowsky D.S., Davis J.M. Dopamine, psychomotor stimulants, and schizophrenia: effects of methylphenidate and the stereoisomers of amphetamine in schizophrenics. Adv Biochem Psychopharmacol 1974, 12:317-323.
32. Janowsky D.S., Davis J.M. Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms. Arch Gen Psychiatry 1976, 33:304-308.
33. Janowsky D.S., Huey L., Storms L., Judd L.L. Methylphenidate hydrochloride effects on psychological tests in acute schizophrenic and nonpsychotic patients. Arch Gen Psychiatry 1977, 34:189-194.
34. Jody D., Lieberman J.A., Geisler S., Szymanski S., Alvir J.M. Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia. Psychopharmacol Bull 1990, 26:224-230.
35. Kim-Cohen J., Caspi A., Moffitt T.E., Harrington H., Milne B.J., Poulton R. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. Arch Gen Psychiatry 2003, 60:709-717.
36. Koreen A.R., Lieberman J.A., Alvir J., Chakos M. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls. Neuropsychopharmacology 1997, 16:61-68.
37. Kraemer M., Uekermann J., Wiltfang J., Kis B. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin Neuropharmacol 2010, 33:204-206.
38. Levy F., Hay D.A., Bennett K.S., McStephen M. Gender differences in ADHD subtype comorbidity. J Am Acad Child Adolesc Psychiatry 2005, 44:368-376.
39. Lieberman J.A., Alvir J., Geisler S., Ramos-Lorenzi J., Woerner M., Novacenko H., et al. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 1994, 11:107-118.
40. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987, 91:415-433.
41. Linnet K.M., Dalsgaard S., Obel C., Wisborg K., Henriksen T.B., Rodriguez A., et al. Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. Am J Psychiatry 2003, 160:1028-1040.
42. Loeber R. Initiation, escalation and desistance in juvenile offending and their correlates. J Crim Law Criminol (1931) 1991, 82:36-82.
43. Lucas A.R., Weiss M. Methylphenidate hallucinosis. JAMA 1971, 217:1079-1081.
44. Lysaker P.H., Vohs J.L., Tsai J. Negative symptoms and concordant impairments in attention in schizophrenia: associations with social functioning, hope, self-esteem and internalized stigma. Schizophr Res 2009, 110:165-172.
45. Mannuzza S., Klein R.G., Bessler A., Malloy P., LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993, 50:565-576.
46. Mannuzza S., Klein R.G., Bessler A., Malloy P., LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998, 155:493-498.
47. Mannuzza S., Klein R.G., Bonagura N., Malloy P., Giampino T.L., Addalli K.A. Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry 1991, 48:77-83.
48. Mannuzza S., Klein R.G., Konig P.H., Giampino T.L. Hyperactive boys almost grown up. IV. Criminality and its relationship to psychiatric status. Arch Gen Psychiatry 1989, 46:1073-1079.
49. Mannuzza S., Klein R.G., Moulton J.L. Lifetime criminality among boys with attention deficit hyperactivity disorder: a prospective follow-up study into adulthood using official arrest records. Psychiatry Res 2008, 160:237-246.
50. Milberger S., Biederman J., Faraone S.V., Wilens T., Chu M.P. Associations between ADHD and psychoactive substance use disorders. Findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict 1997, 6:318-329.
51. Mosholder A. Psychiatric adverse events in clinical trials of drugs for ADHD. FDA Report PID D060163 2006, US Food and Drug Administration, [Last accessed March 26th 2013]. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_10_01_Mosholder.pdf.
52. Niemi L.T., Suvisaari J.M., Tuulio-Henriksson A., Lönnqvist J.K. Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies. Schizophr Res 2003, 60:239-258.
53. Owen M.J., O'Donovan M.C., Thapar A., Craddock N. Neurodevelopmental hypothesis of schizophrenia. Br J Psychiatry 2011, 198:173-175.
54. Pedersen C.B., Gøtzsche H., Møller J.Ø., Mortensen P.B. The Danish Civil Registration System - A cohort of eight million persons. Dan Med Bull 2006, 53:441-449.
55. Phelan K. One year post-pediatric exclusivity postmarketing adverse event review: Adderall XR. FDA Report PID D040761 2006, US Food and Drug Administration, [Last accessed March 26th 2013]. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_05_02_AdderallSafetyReview.pdf.
56. Phelan K. Summary of psychiatric and neurological adverse events from June 2005 1-year post pediatric exclusivity reviews of Concerta and other methylphenidate products 2006, US Food and Drug Administration, [Last accessed March 26th 2013]. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_09_01_Methsummary.pdf.
57. Ross R.G. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2006, 163:1149-1152.
58. Rubino I.A., Frank E., Croce Nanni R., Pozzi D., Lanza di Scalea T., Siracusano A. A comparative study of axis I antecedents before age 18 of unipolar depression, bipolar disorder and schizophrenia. Psychopathology 2009, 42:325-332.
59. Rucklidge J.J. Gender differences in attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2010, 33:357-373.
60. Satterfield J., Swanson J., Schell A., Lee F. Prediction of antisocial behavior in attention-deficit hyperactivity disorder boys from aggression/defiance scores. J Am Acad Child Adolesc Psychiatry 1994, 33:185-190.
61. Satterfield J.H., Faller K.J., Crinella F.M., Schell A.M., Swanson J.M., Homer L.D. A 30-year prospective follow-up study of hyperactive boys with conduct problems: adult criminality. J Am Acad Child Adolesc Psychiatry 2007, 46:601-610.
62. Schmidt K., Freidson S. Atypical outcome in attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1990, 29:566-570.
63. Sharma R.P., Javaid J.I., Pandey G.N., Janicak P.G., Davis J.M. Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients. Biol Psychiatry 1991, 30:459-466.
64. Shen L.H., Liao M.H., Tseng Y.C. Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders. J Biomed Biotechnol 2012, 2012:259349.
65. Sourander A., Elonheimo H., Niemela S., Nuutila A.M., Helenius H., Sillanmaki L., et al. Childhood predictors of male criminality: a prospective population-based follow-up study from age 8 to late adolescence. J Am Acad Child Adolesc Psychiatry 2006, 45:578-586.
66. Szeszko P.R., Bilder R.M., Dunlop J.A., Walder D.J., Lieberman J.A. Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biol Psychiatry 1999, 45:680-686.
67. Uggerby P., Ostergaard S.D., Roge R., Correll C.U., Nielsen J. The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. Dan Med J 2013, 60:A4578.
68. Weiss G., Hechtman L., Milroy T., Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 1985, 24:211-220.
69. World Health Organization International classification of diseases: manual of the international statistical classification of diseases, injuries and causes of death (ICD-8) 1967, WHO, Geneva.
70. World Health Organization The ICD-10 Classification of mental and behavioural disorders: diagnostic criteria for research 1993, World Health Organization, Geneva, Switzerland.